Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ImmVira Granted US Orphan Drug Status for Oncolytic Virus Candidate in Glioma

publication date: Aug 8, 2022

Shenzhen ImmVira reported its oncolytic herpes simplex virus product MVR-C5252 was granted Orphan Drug Designation in the US to treat malignant glioma. The oHSV delivery system is designed to treat glioma by specific attenuation that promotes on-target malignant gliocyte killing while preventing off-target activity. ImmVira says MVR-C5252 is the only oncolytic virus brain tumor therapy that carries specific exogenous genes to cause an immune response in the tumor microenvironment. ImmVira’s first three oncolytic virus products are currently undergoing five Phase I/Phase II trials in the US and China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022